Detecting lung cancer in plasma with the use of multiple genetic markers

International Journal of Cancer

Volumn 108, Issue 1, 2004, Pages 91-96

  Andriani, Francesca ^a   Conte, Davide ^a   Mastrangelo, Tiziana ^a   Leon, MariaElena ^b   Ratcliffe, Cathy ^a   Roz, Luca ^a   Pelosi, Giuseppe ^b   Goldstraw, Peter ^c   Sozzi, Gabriella ^a   Pastorino, Ugo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Early detection; FHIT; Genetic markers; Lung cancer; p53

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; MICROSATELLITE DNA; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CHROMOSOME 3; CONTROLLED STUDY; DNA SEQUENCE; EVALUATION; FEMALE; GENE MUTATION; GENETIC MARKER; HUMAN; HYBRIDIZATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ACID ANHYDRIDE HYDROLASES; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOMES, HUMAN, PAIR 3; DNA, NEOPLASM; FEMALE; GENES, P53; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS;

EID: 0345687975     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11510     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
2. Berlin NI, Buncher CR, Fontana RS, Frost JK, Melamed MR. The National Cancer Institute Cooperative Early Lung Cancer Detection Program: results of the initial screen (prevalence)-early lung cancer detection, introduction. Am Rev Respir Dis 1984;130:545-9.
3. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK, Smith JP. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99- 105.
4. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
5. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
6. Rodenhuis S, Slebos RJC, Boot AJM, Evers SG, Mooi WJ, Wagenaar SS, Van Bodegom PC, Bos JL. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the lung. Cancer Res 1988;48:5738-41.
7. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Otha M, Huebner K, Croce CM. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
8. Fong KM. Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing abberations. Cancer Res 1997;57:2256-67.
9. Hung J, Kishimoto Y, Sugio K. Virmani A, McIntire D. Minna JD, Gazdar AF. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 1995;273:558.
10. Thiberville L, Payne P, Vielkinds J, LeRiche J, Horsman D, Nouvet G, Palcic B, Lam S. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res 1995;55:5133-9.
11. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG. Aberrant methylation of p16(INK4a) is an early event in lung cancer and potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11891-6.
12. Hirsch FR, Franklin WA, Gazdar AF, Bunn PA Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 2001;7:5-22.
13. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
14. Sozzi G, Musso K. Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res 1999;5:2689-92.
15. Bearzatto A, Conte D, Frattini M, Zaffaroni N, Andriani F, Balestra D, Tavecchio L, Daidone MG, Sozzi G. p161NK4A hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 2002;8:3782-7.
16. Leon SA, Shapiro B, Sklaroff DM, Yaros J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50.
17. Shapiro B, Chakrabarty M, Cohn EM. Leon SA. Determination of circulating DNA levels in patients with bening or malignant gastrointestinal disease. Cancer 1983;51:2116-20.
18. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
19. Chang HW, Lee SM, Goodman SN, Singer G, Cho SK, Sokoll LJ, Montz FJ, Roden R, Zhang Z, Chan DW, Kurman RJ, Shih IM. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst 2002;94:1697-703.
20. Sozzi G, Conte D, Mariani L, Lo Vullo S. Roz L, Lombardo C, Pierotti MA, Tavecchio L. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001;61:4678.
21. Pelosi G. Pasini F, Olsen Stenholm C, Pastorino U, Maisonneuve P, Sonzogni A, Maffini F, Pruneri G, Fraggetta F, Cavallon A, Roz E, Iannucci A, Bresaola E, Viale G. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 2002;198:100-9.
22. Kirk GD, Camus-Randon AM, Mendy M, Goedert JJ, Merle P, Trèpo C, Brèchot C, Hainaut P. Montesano R. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from the Gambia. J Natl Cancer Inst 2000;92:148-53.
23. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998;58:5032-7.
24. Anker P, Lyautey J, Lederrey C, Stroun M. Circulating nucleic acids in plasma or serum. Clin Chim Acta 2001;313:143-6.
25. Mao L, Schoenberg MP, Scicchitano M, Erozan YS, Merlo A, Schwab D, Sidransky D. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996;271:659-62.
26. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC Tp53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002:19:607-14.
27. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, Herman JG, Wu L, Decker PA, Jen J, Sidransky D. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999;91:332-9.
28. Garcia JM, Silva JM, Dominguez G, Silva J, Bonilla F. Heterogeneous tumor clones as an explanation of discordance between plasma DNA and tumor DNA alterations. Genes Chromosomes Cancer 2002; 31:300-1.
29. Denissenko MF, Koudriakova TB, Smith L, O'Connor TR, Riggs AD, Pfeifer GP. The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene 1998; 17:3007-14.
30. Denissenko MF. Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[alpha]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430.
31. Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L. Shields PG, Hewer A, Phillips DH, Ryberg D, Haugen A, Harris CC. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res 2001;61:6350-5.